MedTrace Logo

CADx - Radiomics to Distinguish the Origin of Ovarian Tumors

NCT05174377 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 600

Last updated 2022-01-25

No results posted yet for this study

Summary

In women with an ovarian tumor, it is often unclear whether the tumor is benign or malignant. To differentiate, tumor markers (CA125 and CEA), a transvaginal ultrasound and, depending on the ultrasound image and the CA125 concentration, a CT scan are performed. The quality of radiological imaging in diagnosing abdominal pathology is often not accurate enough, making additional interventions no-dig for proper classification and interpretation of the tumor.

Objective: To improve accuracy for distinguishing benign from malignant disease in patients presenting with an ovarian mass by using a computer aided detection algorithm.

Conditions

Interventions

DIAGNOSTIC_TEST

CT-scan algorithm

CADx model was developed with a Support Vector Machine (SVM) algorithm and trained using five-fold cross-validation

Sponsors & Collaborators

  • The Netherlands Cancer Institute

    collaborator OTHER

  • Eindhoven University of Technology

    collaborator OTHER

  • Amsterdam UMC, location VUmc

    collaborator OTHER

  • Leiden University Medical Center

    collaborator OTHER

  • Amphia Hospital

    collaborator OTHER

  • Gynaecologisch Oncologisch Centrum Zuid

    lead OTHER

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-05
Primary Completion
2024-08-01
Completion
2025-08-01

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05174377 on ClinicalTrials.gov